. 2021 Jun 10;12:690821. doi: 10.3389/fimmu.2021.690821

Table 2.

Complement functional assays performed in this study using patient sera and mutant constructs.

Complement assays	Patient 1		Patient 2		Patient 3		Positive control D279G	Normal controls
Complement assays	D371G		E601K		I242L		Positive control D279G	Normal controls
	Serum^a	Mutant construct	Serum^a	Mutant construct	Serum^a	Mutant construct	Mutant construct	Serum	Wild-type construct
C3 deposition on glomerular endothelial cells	+	ND	+	ND	+	ND	ND	3/10^b	ND
Hemolysis sheep RBCs	+	ND	–	ND	+	ND	ND	0/2	ND
Factor B binding to C3b (surface plasmon resonance)	ND	+	ND	–	ND	–	+	ND	–
Factor B degradation by factor D	Degr	Degr	Degr	Degr	Degr	Degr	Degr	Degr	Degr
Hemolysis of rabbit RBCs	ND	+	ND	–	ND	–	+	ND	–
Soluble C5b-9 release from glomerular endothelial cells	ND	+	ND	–	ND	–	+	ND	–

^aSerum from Patients 1 and 2 was taken during eculizumab treatment. Serum from Patient 3 was taken before the start of eculizumab treatment. ^b3/10 indicates positive result in 3 of 10 controls. +, complement activation detected; -, complement activation was not detected; ND, Not done; RBCs, red blood cells; Degr, degradation detected.